Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- Check4 days agoChange DetectedThe page revision indicator was updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check11 days agoChange DetectedThe page shows a minor version revision from v3.2.0 to v3.3.1, with no changes to study content, eligibility criteria, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange DetectedRemoved the government funding lapse notice; no core study content or eligibility information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check32 days agoChange DetectedMinimal changes detected: only minor layout/UI updates with no impact on core study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedMajor update: new operating-status notice and v3.2.0 release replaces v3.1.0; core content about status and transaction processing updated.SummaryDifference3%

- Check68 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.